Gossamer Bio Inc
(FRA:4GB)
€
0.7705
0.0095 (1.25%)
Market Cap: 182.56 Mil
Enterprise Value: 39.46 Mil
PE Ratio: 0
PB Ratio: 2.46
GF Score: 36/100 Gossamer Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020 / 06:10PM GMT
Release Date Price:
€10.5
(-4.55%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good afternoon. I'm Andrea Tan from the biotechnology team at Goldman Sachs, and I'm pleased to be joined by Gossamer Bio. With us, we have Sheila Gujrathi, CEO; and Bryan Giraudo, CFO. Thanks for joining us today. Sheila, I'll turn it over to you for some opening remarks.
Sheila K. Gujrathi
Gossamer Bio, Inc. - Co-Founder, President, CEO & Director
Well, thank you so much for inviting us to the Goldman Healthcare Conference. We're really pleased to be here and looking forward to jumping into Q&A, and I have some slides here I can present along the way. But thank you, again, for including us.
Questions & Answers
Andrea R. Tan;Sheila K. Gujrathi
Goldman Sachs Group, Inc., Research Division - Research Analyst;Gossamer Bio, Inc.
Perfect. So maybe to start, can you provide a high-level overview of the company and some thoughts on how the company has advanced in the year plus since your IPO?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot